Multiple Sclerosis May Now Be Predicted Through Fatigue And Leg Dysfunction, Experts Say
A new study has recently suggested that fatigue and lower limb problems may have the ability to predict conversion from relapsing-remitting to secondary progressive MS in the long run. Researchers say that Multiple Sclerosis, being a disabling disease of the central nervous system that disrupts communication between the brain and the body, is more likely to progress to advanced disease among patients who suffer from fatigue and limited use of their legs. It was found that nearly 80 percent to 85 percent of people with multiple sclerosis are first diagnosed with relapsing-remitting MS, which includes periods of remission between flare-ups.
Fatigue And Leg Dysfunction As MS Determiner
In one of his her statements reported by MedPage Today, study lead author Dr. Bianca Weinstock-Guttman together with her team from the New York State Multiple Sclerosis Consortium (NYSMSC), have explained that better understanding as to who is at a higher risk of getting worse may eventually allow them to tailor more specific treatments to these people. Dr. Weinstock-Guttman explains that these two factors were the only significant predictors of disease progression over 5 years in patients who had the disease for many years. Additionally, the researchers said that the presence of these symptoms should induce an increased concern, and physicians should consider more appropriate therapies, such as change to a more efficacious disease-modifying therapy while re-emphasizing the importance of active exercise, improved diet, the significance of sleep, and a general attention to wellness.
Furthermore, according to reports revealed by Medical Xpress, in conducting the study, the researchers had evaluated 155 people, whose age were 50 and older, and who had been diagnosed with relapsing-remitting multiple sclerosis at least 15 years earlier, highlighting the fact that all of the patients' symptoms and their levels of disability were assessed when the study began. The researchers found that these patients were four times as likely to experience fatigue which has been supported when the team had considered other possible contributing factors, such as age, time since diagnosis and the severity of their disability. Consequently, Weinstock-Guttman has claimed that although more research is vital, their study allegedly brings them closer to understanding which older adults with MS may be at higher risk of getting worse.
The Study's Proposition
Meanwhile, the team finds that while the precise cause of fatigue in patients with MS is yet to be completely explained, they believe that it is most likely a result of the underlying complex inflammatory and neurodegenerative processes that characterize MS. Ultimately, the researchers say that fatigue may be a more sensitive indicator of the extent of the injury in the central nervous system, similar to patient-reported lower extremity dysfunction, which may not be fully assessed or gauged during a short neurological exam.
SpaceX’s Private Moon Venture Announcement: What's NASA's Take On That?
Following after SpaceX’s revelation about their private moon flight taking place next year, what does NASA have to say about it? What’s the truth behind claims that NASA was pleased about the said venture? Find out what authorities have to say
Carfilzomib Could Be More Effective In Treating Relapsed Multiple Myeloma
Considering the therapeutic claims of Carfilzomib and Bortezomib, which drug has a good potential in treating Relapsed Multiple Myeloma? What’s the truth behind claims that Carfilzomib can allegedly have a higher chance of curing the disease? Could this be the cure that a lot of people have been waiting? Find out what experts have to say
HIV News: Woman’s Reproductive Tract Might Hold The Key For The Disease
What is this protein that’s allegedly found in a woman’s reproductive tract that might hold the key to answer the problem in HIV? Considering the continuous efforts to eradicate one of the world’s long dreaded diseases, could Geelong scientists finally shed the light to HIV? Find out what experts have to say
The Controversial ‘Liberation Therapy’: Is It Good For Multiple Sclerosis?
With the number of advancements that has been intended for Multiple Sclerosis, why is the so-called ‘Liberation Therapy’ found to ineffective? What makes the said therapy to be considered as a failure when it comes to treating the auto-immune disease? Could it mean that it’s now a hopeless case for one of the world’s most dreaded diseases? Here’s what experts have to say
Recovery From Multiple Sclerosis Found In The So-Called 'tDCs' Technology, Details Inside
What is 'tDCs'? Considering that Multiple Sclerosis has been one of the world's fast emerging diseases, can the cure be found in this new technology called 'tDCs'? How can a patient recover from the aid auto-immune disease with the help of this technology? Here's what health professionals have to say
Apitope's Peptide Vaccine Finally Sheds Light To Multiple Sclerosis; Details Inside
With the continuous efforts to eradicate Multiple Sclerosis, how significant is Apitope's peptide vaccine for the said auto-immune disease? Could this vaccine be the advent of new medications to treat one of the diseases that has already affected millions of lives? Find out what experts have to say
MORE IN ITECHPOST
Fujifilm Continues Research on Avigan as COVID-19 Drug into June: Japanese Prime Minister Shinzo Abe Optimistic
The film company Fujifilm continues its research into June as the Japanese Prime Minister would approve the upcoming drug as a COVID-19 treatment.
SpaceX, NASA's Historic Astronaut Launch in the US Threatened by Disruptive Weather Delay
SpaceX, NASA prepares to send the first Astronaut-manned launch into space from the US in nearly 10 years. Will the weather cooperate with their launch this Wednesday?
4 Phantasy Star Online 2 Beginner Tips You Should Know Before PC Download
Phantasy Star Online 2 is almost releasing on PC! Here are a few things to know about the game to turn you from a beginner to a pro.